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Nine-valent human papilloma virus vaccineBackground: A nine-valent human papilloma virus (9vHPV) vaccine has been developed to prevent infec-
tions and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV (qHPV) vaccine) as
well as to five additional oncogenic HPV types (HPV 31/33/45/52/58). The 9vHPV vaccine has the poten-
tial to prevent 90% of cervical cancers, HPV-related anal, vaginal and vulval cancers and anogenital warts.
We compared the immunogenicity and safety of the 9vHPV vaccine versus the qHPV vaccine in 16–26-
year-old men.
Methods: Participants (N = 500) were randomised to receive 9vHPV or qHPV vaccines on day 1, month 2
and month 6. Serology testing was performed on day 1 and month 7. HPV type-specific antibody titres
(anti-HPV 6/11/16/18/31/33/45/52/58) were determined by competitive Luminex immunoassay and
expressed as geometric mean titres and seroconversion rates. Vaccine safety was also assessed.
Results: The HPV 6/11/16/18 immune responses elicited by the 9vHPV vaccine were comparable with
those elicited by the qHPV vaccine. All participants receiving the 9vHPV vaccine seroconverted for HPV
31/33/45/52/58. The 9vHPV and qHPV vaccines showed comparable safety profiles.
Conclusions: In addition to immune responses to HPV 31/33/45/52/58, a three-dose regimen of the
9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV
vaccine in men aged 16–26 years. The safety profile was also similar for the two vaccines. The results
from this study support extending the efficacy findings with qHPV vaccine to 9vHPV vaccine in men aged
16–26 years.
NCT02114385
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction & Co. Inc., Kenilworth, NJ, USA) was developed to provide protec-A nine-valent human papilloma virus (types
6/11/16/18/31/33/45/52/58) (9vHPV) vaccine (Gardasil 9, Mercktion against the HPV types already covered by the quadrivalent
HPV (types 6/11/16/18) (qHPV) vaccine and the next five most
common oncogenic types associated with cervical cancer world-
wide (types 31/33/45/52/58) [1]. The 9vHPV vaccine could poten-
tially prevent approximately 90% of cervical cancers, 90% of HPV-
related vulval, vaginal and anal cancers and 90% of genital warts
worldwide [2–7]. The 9vHPV vaccine was licensed in 2014 in the
USA, and in 2015 in Canada, the EU and Australia.
In clinical trials in women aged 16–26 years, the qHPV vaccine
prevented infection and cervical/vaginal/vulval dysplasia caused
by HPV 6/11/16/18 as well as HPV 6/11-related condyloma. In a
clinical trial in men aged 16–26 years, the qHPV vaccine prevented
genital and anal infection and anal dysplasia caused by HPV
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these results, the qHPV vaccine has been widely licensed for use in
both genders.
In a clinical trial conducted in women aged 16–26 years, the
9vHPV vaccine prevented infection and disease caused by HPV
31/33/45/52/58. It also induced anti-HPV 6/11/16/18 antibody
responses that were non-inferior to responses induced by the
qHPV vaccine; efficacy of the 9vHPV vaccine against infection
and disease caused by HPV 6/11/16/18 in women aged 16–26 years
was inferred based on these results [10].
In another clinical trial, the 9vHPV vaccine induced non-inferior
anti-HPV antibody responses to HPV 6/11/16/18/31/33/45/52/58
in men aged 16–26 years versus women aged 16–26 years. Efficacy
of the 9vHPV vaccine against infection and disease caused by the
nine vaccine HPV types in men aged 16–26 years was inferred
based on these results [11].
In this report, we compare the safety and immunogenicity of
the 9vHPV and qHPV vaccines in men aged 16–26 years, and assess
whether the 9vHPV vaccine induced non-inferior anti-HPV
6/11/16/18 antibody responses compared with the qHPV vaccine.
The study aims at supporting the extension of the efficacy findings
with qHPV vaccine to 9vHPV vaccine in men aged 16–26 years.2. Materials and methods
We conducted a double-blind, randomized, controlled, with
qHPV vaccine, immunogenicity and safety study of the 9vHPV vac-
cine in young men 16–26 years of age. Participants were enrolled
from seven centres located in three countries (Belgium, Germany,
and the Netherlands). The study was conducted in accordance with
the principles of Good Clinical Practice, as well as the Declaration
of Helsinki, the Ethical Principles for Medical Research Involving
Human Subjects of the World Medical Association, the Interna-
tional Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use, and national
and local relevant guidelines and requirements regarding ethical
committee review. This trial is registered with Clinicaltrials.gov
number NCT02114385.
2.1. Population
The study was designed to enrol 500 males aged P16 to
<27 years who were in good physical health and had a history of
no more than five lifetime female and no male sexual partners
(the immunogenicity of the 9vHPV vaccine in men having sex with
men (MSM) was assessed in another study [11]; see Section 4 for
further information). Reasons for exclusion from the study
included known allergy to any component of the vaccine, a previ-
ous history of a severe allergic reaction, thrombocytopenia, coagu-
lation disorder, or a positive HPV test, concurrent participation in
any other clinical trial of an investigational medicinal product,
and previous vaccination with a marketed HPV vaccine or partici-
pation in a previous HPV vaccine clinical trial (active agent or pla-
cebo). Individuals who were immunocompromised (including
those who had a splenectomy), received immunosuppressive ther-
apy in the previous year, received immunoglobulin or a blood-
derived product within the previous 6 months, or had a history
of any condition that could confound study results or interfere
with participation in the study were also excluded.
2.2. Randomization
An Interactive Web Response System (IWRS) was used to allo-
cate participants to 9vHPV or qHPV vaccine in a blinded manner.
The system assigned an allocation number from a randomized,age-stratified (16–17 years and 18–26 years) allocation schedule.
The IWRS ensured that at least 75 participants (15%) aged 16–
17 years were randomized in order to avoid underrepresentation
of minor participants; whenever necessary, randomization of par-
ticipants aged 18 years or older was stopped when 425 of these
participants had been randomized in the study. Participants were
randomized in a 1:1 ratio using blocks of randomization (size 8)
within each age stratum to 9vHPV or qHPV vaccine.
2.3. Study vaccination
All participants were administered a 3-dose regimen of 9vHPV
or qHPV vaccine at day 1, month 2, and month 6. Each vaccine dose
was administered as a 0.5-mL intramuscular injection. Vaccination
was deferred if a participant had an oral temperatureP37.8 C for
24 h prior to vaccination.
2.4. Vaccine immunogenicity
Blood samples were drawn at day 1 (immediately before vacci-
nation) and at month 7. Serum collected from all participants at
day 1 and month 7 was analyzed for antibodies to the nine vaccine
HPV types by competitive Luminex immunoassay (cLIA; HPV-9
cLIA Version 2.0; performed by PPD Vaccines and Biologics Lab,
Wayne, PA, USA) [12]. Because antibody titres to each individual
HPV type were determined using type-specific monoclonal anti-
bodies, it is not possible to directly compare assay results across
HPV types.
The primary immunogenicity objective was to show that geo-
metric mean titres (GMTs) at month 7 for anti-HPV 6/11/16/18
in the 9vHPV vaccine group would be non-inferior to the GMTs
at month 7 in the qHPV vaccine group. The secondary immuno-
genicity objectives were to provide a summary of GMTs and sero-
conversion rates at month 7 for all nine HPV types (HPV
6/11/16/18/31/33/45/52/58).
Serology results at day 1 were part of the criteria to define the
per-protocol analysis populations. Participants who were seropos-
itive to a vaccine HPV type at day 1 were excluded from the per-
protocol immunogenicity analysis for the corresponding HPV type.
2.5. Vaccine safety and tolerability
Following each vaccination, participants were observed for
P30 min for any untoward effects, including allergic reactions.
All participants received a vaccination report card (VRC) at each
vaccination visit. They were asked to record their oral temperature
on the VRC from day 1 to day 5 after each vaccination (starting on
the evening after vaccination), and any injection-site and systemic
adverse events (AEs) for a total of 15 days including the day of vac-
cination. The study site personnel reviewed the VRC for complete-
ness and could not alter the original information recorded by the
participants on the VRC. The investigator determined the causality
of systemic AEs reported on the VRC, and classified each AE
reported on the VRC as a serious or non-serious AE.
An oral temperatureP37.8 C during the follow-up period was
considered an elevated temperature (fever). For each AE, partici-
pants were asked to rate the symptom as mild (awareness of sign
or symptom but easily tolerated), moderate (discomfort enough to
cause interference with usual activities), or severe (incapacitating
with inability to work or do usual activity); injection-site AEs of
swelling and erythema were rated by size. Investigators were
instructed to assign causality to AEs on the basis of exposure, time
course, likely cause, and consistency with the vaccine’s known
profile.
Serious AEs (SAEs) were predefined as any AE that resulted in
death, deemed by the investigator to be life-threatening, or that
P. Van Damme et al. / Vaccine 34 (2016) 4205–4212 4207resulted in a persistent or significant disability or incapacity,
resulted in or prolonged an existing in-patient hospitalization, or
was a congenital anomaly, a cancer, or an ‘other important medical
event’. SAEs were collected for the entire duration of the study irre-
spective of cause.
2.6. Statistical methods
HPV specific per-protocol sets were to comprise participants
who received all three vaccinations, had a month 7 serology result,
were seronegative for the corresponding HPV type at day 1, and
had no protocol violations that could interfere with immune
responses. It was estimated that there would be approximately a
25% exclusion rate from each per-protocol set, leaving 185/250
evaluable participants per vaccine group for the primary analysis.
The non-inferiority margin was set at 0.5, the true GMT ratio
was estimated to be 1.0 for HPV6, 16 and 18 and 0.75 for HPV11,
and the standard deviation (natural log scale) was estimated at
1.2 (for HPV 16,18, 6 and 11 post-vaccination titres). Based on
these parameters, the study has greater than 90% power to demon-
strate the non-inferiority of the HPV 6/11/16/18 GMTs following
vaccination with the 9vHPV vaccine versus the qHPV vaccine.
Immunogenicity results are presented for the per-protocol sets.
Non-inferiority of anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-
HPV 18 GMTs was demonstrated by four one-sided tests (one for
each HPV type) conducted at a = 0.025 level (one-sided). Non-
inferiority was achieved if the lower bound of the two-sided 95%
CI for the GMT ratio (post-dose 3 9vHPV vaccine GMT/post-dose
3 qHPV vaccine GMT) was greater than 0.5. Each test was con-
ducted using an analysis of variance (ANOVA) model with a
response of log individual titres and a fixed effect for group and
age strata (as per randomisation). Descriptive statistics were used
for all other immunogenicity analyses. Confidence intervals for
seroconversion rates were calculated using the exact method for
binary variables as proposed by Collett [13].
Safety analyses are described for the safety set (all participants
who received at least one study vaccine dose and for whom safety
follow-up data were available).3. Results
Overall, 502 individuals were screened for inclusion in the
study (between 24 March 2014 and 17 September 2014), of whom
500 (the randomized set) were included in the study and random-
ized to the 9vHPV or qHPV vaccine groups (Fig. 1). The baseline
characteristics of randomized participants were generally similar
between vaccine groups (Table 1). The mean age at the first vacci-
nation visit was 21.0 years. The most common reason for exclusion
from the per-protocol immunogenicity (PPI) sets was having a
month 7 serum sample or result missing or being seropositive at
day 1 for one of the vaccine HPV types (Table 2).
3.1. Immunogenicity
As seen in Table 3, anti-HPV 6, anti-HPV 11, anti-HPV 16 and
anti-HPV 18 GMTs elicited by the 9vHPV vaccine were non-
inferior to those elicited by the qHPV vaccine (the lower bound
of the two-sided 95% CI for the GMT ratio [9vHPV vaccine/qHPV
vaccine] was P0.5, P < 0.001; Table 3).
Anti-HPV 6, anti-HPV 11, anti-HPV 16 and anti-HPV 18 GMTs
were numerically higher in the younger age stratum (16–17 years)
than the older age stratum (18–26 years) and comparable within
each age stratum for both vaccines (Table 3).
All participants seroconverted for HPV 6/11/16/18 after receiv-
ing three doses of the 9vHPV vaccine or qHPV vaccine, except forseven participants who did not seroconvert to HPV 6 (four having
received the 9vHPV vaccine and three the qHPV vaccine), and two
participants who did not convert to HPV 18 (one in each group).
These participants who were all in the 18–26 year stratum, had
no relevant medical history reported at baseline, except for one
participant with a medical history of seronegative rheumatoid
arthritis reported at baseline, and prior/concomitant treatment
with Plaquenil starting the previous year and ending nine days
after dose 2, and one participant who received concomitant treat-
ment with Decortin H, 40 mg/day for eight days ending seven days
before dose 3 to treat obstructive bronchitis. These participants
also had low immune responses to the other HPV types, with anti-
body titres generally 2–47-fold lower than the GMTs.
As shown in Table 3, marked HPV 31/33/45/52/58 antibody
responses were measured post-dose 3 in the 9vHPV vaccine group.
Anti-HPV 31/33/45/52/58 GMTs post-dose 3 were numerically
greater by at least twofold and up to 15-fold in the 9vHPV vaccine
group compared with the qHPV vaccine group. Numerically higher
anti-HPV 31/33/45/52/58 GMTs were observed in 16–17 year olds
compared with 18–26 year olds. Seroconversion rates after dose 3
were 100% for HPV 31/33/45/52/58 among participants who
received three doses of the 9vHPV vaccine. Anti-HPV
31/33/45/52/58 GMTs post-dose 3 were low in the qHPV vaccine
group. Nonetheless, the qHPV vaccine induced measurable levels
immune response to the HPV types not included in the vaccine
(post-dose 3 GMTs can be seen in Table 3), including seroconver-
sion rates after dose 3 as high as 61.6% for HPV 31 and 36.1% for
HPV 58 (Table 4).
3.2. Safety/tolerability
Most participants reported at least one AE over the course of the
study, including 81.5% and 79.0% of participants in the 9vHPV and
qHPV vaccine groups, respectively, who experienced vaccine-
related AEs from day 1 to day 15 following any vaccination
(Table 5).
Most participants reported at least one injection-site reaction
from day 1 to day 5 following either vaccination (9vHPV vaccine:
79.0%; qHPV vaccine: 72.2%). Although more participants reported
injection-site pain and swelling after receiving the 9vHPV vaccine
(77.8% and 14.5%, respectively) compared with the qHPV vaccine
(70.2% and 9.3%, respectively), these differences did not reach sta-
tistical significance (P = 0.053 and P = 0.072, respectively). More-
over, no participant reported severe injection-site pain, and
severe injection-site swelling (>5 cm) was reported in a similar
proportion of participants in each vaccine group (9vHPV vaccine:
1.2%; qHPV vaccine: 1.6%).
Comparable percentages of participants in each vaccine group
reported vaccine-related systemic AEs (23.0% and 21.8% of partici-
pants in the 9vHPV and qHPV vaccine groups, respectively). The
most common vaccine related systemic AEs in the 9vHPV vaccine
group were headache (8.1%), lymphadenopathy (2.4%), pyrexia
(2.0%), fatigue (2.0%), nausea (2.0%), diarrhea (2.0%), nasopharyngi-
tis (1.6%), myalgia (1.6%), dizziness (1.2%) and oropharyngeal pain
(1.2%). Among participants receiving the qHPV vaccine, the most
frequent vaccine-related systemic AEs were headache (8.9%), fati-
gue (3.2%), pyrexia (2.8%), diarrhoea (2.4%), nasopharyngitis
(1.6%) and nausea (1.2%).
No vaccine-related SAEs and no discontinuations due to an AE
were reported. Six SAEs were reported for six participants (all in
the qHPV vaccine group), including joint dislocation (left shoulder
dislocation during sport activities) 21 days post-dose 1, ligament
injury (trauma to the cruciate ligaments of the left knee during
sport activities) 34 days post-dose 2, ligament rupture (rupture
of the anterior cruciate ligament of the right knee during sport
activities) 44 days post-dose 2, foot fracture (tarsometatarsal
Screened
N=502
9vHPV vaccine
n=249
qHPV vaccine
n=251
9vHPV vaccine
n=249
qHPV vaccine
n=251
Screen failures (N=2)
Withdrawal by participant 3 1
Lost to follow-up – 2
9vHPV vaccine
n=246 (98.8%*)
qHPV vaccine
n=248 (98.8%*)
Withdrawal by participant – 1
Lost to follow-up – 3
9vHPV vaccine
n=246 (98.8%*)
qHPV vaccine
n=244 (97.2%*)
9vHPV vaccine
n=246 (98.8%*)
qHPV vaccine
n=243 (96.8%*)
Lost to follow-up – 1
*Percentages are calculated based on the number of randomised participants
Randomised
N=500
Received dose 1
n=500
Received dose 2
n=494 (98.8%*)
Received dose 3
n=490 (98.0%*)
Completed the study
n=489 (97.8%*)
Withdrawals (n=1) 9vHPV vaccinen=0
qHPV vaccine
n=1
Withdrawals (n=4) 9vHPV vaccinen=0
qHPV vaccine
n=4
Withdrawals (n=6) 9vHPV vaccine
n=3
qHPV vaccine
n=3
Fig. 1. A summary of the disposition of participants throughout the study, from screening to study completion.
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post-dose 3, concussion (head injury following a traffic accident)Table 1
Demographic characteristics – randomised set (N = 500).
9vHPV vaccine
N = 249
qHPV vaccine
N = 251
All
N = 500
Age at first dose Mean (SD) 20.8 (2.7) 21.3 (3.0) 21.0 (2.8)
Range 16.0–26.0 16.0–26.0 16.0–26.0
16–17 years old n 37 38 75
Mean (SD) 16.4 (0.5) 16.4 (0.5) 16.4 (0.5)
18–26 years old n 212 213 425
Mean (SD) 21.6 (2.1) 22.1 (2.3) 21.8 (2.2)
Weight (kg) Mean (SD) 75.2 (10.9) 74.2 (11.0) 74.7 (11.0)
Range 50–111 47–115 47–115
Height (cm) Mean (SD) 181.9 (7.6) 181.7 (7.1) 181.8 (7.3)
Range 161–202 160–204 160–204
N, number of randomised participants in the respective vaccination group; n,
number of participants contributing to the analysis; SD, standard deviation.28 days post-dose 3, and cytomegalovirus infection (with subse-
quent hospitalization due to high fever) 32 days post-dose 3.4. Discussion
We have compared the immunogenicity of the 9vHPV and qHPV
vaccines in young men aged 16–26 years. We found that adminis-
tration of a three-dose regimen of 9vHPV vaccine generated similar
antibody responses to HPV types 6/11/16/18 compared with a
three-dose regimen of the qHPV vaccine. HPV 6/11/16/18 antibody
responses at 1 month after dose 3 were non-inferior in the 9vHPV
vaccine group compared with the qHPV vaccine group. Thus, the
primary objective of the study was met. Based on these results,
the efficacy of the 9vHPV vaccine can be inferred to be comparable
to that of the qHPV vaccine for preventing infection and disease
related to HPV 6/11/16/18.
The AE profile was generally similar for both vaccines. Injection-
site reactions were more common in the 9vHPV vaccine than in the
qHPV vaccine group. This may be a consequence of the higher dose
Table 2
Summary of exclusions from the per-protocol analyses.
9vHPV vaccine
(N = 249)
qHPV vaccine
(N = 251)
Participants who received P1
injection
249 251
Per-protocol immunogenicity sets (PPI)
PPI for HPV 6 228 226
PPI for HPV 11 228 226
PPI for HPV 16 234 237
PPI for HPV 18 234 236
PPI for HPV 31 234 237
PPI for HPV 33 236 236
PPI for HPV 45 232 236
PPI for HPV 52 235 236
PPI for HPV 58 232 233
Reasons for exclusion
Participants with protocol deviations 13 11
Administration of incorrect clinical
material
1 0
Incomplete vaccination schedule 3 7
Month 7 serum sample outside of
acceptable day range
3 2
Month 7 serum sample or results
missing
3 8
Received non-study live vaccine 1 0
Received non-study inactivated/
recombinant vaccinea
2 0
Vaccination out of the acceptable
day rangesb
3 1
Day 1 seropositivec
HPV 6 5 12
HPV 11 3 6
HPV 16 2 3
HPV 18 2 5
HPV 31 2 4
HPV 33 0 5
HPV 45 4 5
HPV 52 1 5
HPV 58 4 8
Participants are counted once in each applicable category. A participant may appear
in more than one category.
a Includes any live vaccine received 21 days prior to or 14 days following study
vaccine.
b Includes any inactivated or recombinant vaccine received within 14 days of
study vaccine.
c Seropositive at day 1 to the relevant HPV type(s) applies to the PPI set for the
relevant HPV type(s) only.
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with the qHPV vaccine. It should be noted that HBVaxPro 10 lg
(Sanofi Pasteur MSD, Lyon, France, manufactured by Merck & Co.,
Kenilworth, NJ, USA), which contains the same quantity of the
same adjuvant as the 9vHPV vaccine, has been widely adminis-
tered to children and young adults and has a proven favourable
safety profile [14]. Furthermore, no participant withdrew from
the study due to injection-site reactions; thus, we do not anticipate
that injection-site reactions would have a significant impact on
vaccine uptake. Overall, these results are consistent with the
results of previous studies which showed similar AE profiles for
9vHPV vaccine and qHPV vaccine in 16–26-year-old women and
9–15-year-old girls [10,15].
A 9vHPV vaccine dose formulation was selected in Phase II
studies conducted in 16–26-year-old women based on the induc-
tion of non-inferior anti-HPV 6/11/16/18 antibody responses com-
pared with qHPV vaccine [16]. This result was confirmed in Phase
III studies in 16–26-year-old women and 9–15-year-old girls
[10,15]. A similar analysis in 9–15-year-old boys was not deemed
necessary because the immunogenicity of 9vHPV vaccine and
qHPV vaccine are similar in 9–15-year-old boys and girls [17,18],and the two vaccines have similar immunogenicity in 9–15-year-
old girls [15]. The current study demonstrates non-inferior anti-
HPV 6/11/16/18 antibody responses in 16–26-year-old men. Col-
lectively, these results support the conclusion that in males and
females aged 9–26 years, 9vHPV vaccine and qHPV vaccine have
similar immunogenicity profiles with respect to HPV 6/11/16/18.
There are several limitations to our study. The clinical efficacy
of 9vHPV vaccine was not assessed in males. Since the licensed
qHPV vaccine prevents anal pre-cancers due to HPV 16/18, using
a placebo would not be acceptable in an efficacy study. Thus an
efficacy study would require a comparison between the investiga-
tional 9vHPV vaccine and the licensed qHPV vaccine. Since both
qHPV vaccine and 9vHPV vaccine are highly efficacious against
HPV 6/11/16/18, a low incidence of HPV 6/11/16/18-associated
disease is expected with both vaccines. For this reason, an efficacy
comparison of the 9vHPV versus qHPV vaccine would require a
prohibitively large sample size [19]. The clinical efficacy of 9vHPV
vaccine with respect to HPV 6/11/16/18-related infection and dis-
ease was inferred in 16–26-year-old women based on the demon-
stration of non-inferior immunogenicity compared with qHPV
vaccine [10]. Using the same approach, efficacy findings with qHPV
vaccine in 16–26-year-old men can be extended to 9vHPV vaccine
based on the results from this study. The clinical efficacy of the
9vHPV vaccine in preventing HPV 31/33/45/52/58-related infec-
tion and disease was demonstrated in a clinical study in 16–26-
year-old women [10]; these efficacy findings were extended to
16–26-year-old men based on the demonstration of non-inferior
immunogenicity compared with 16–26-year-old women in
another study [11].
Our study was conducted in heterosexual men (HM): the
immunogenicity of HPV vaccines is lower in MSM than in HM
[11,20]. Therefore, analyses of HPV vaccine immunogenicity should
be conducted separately in HM and MSM. The immunogenicity of
9vHPV vaccine and qHPV vaccine in HM and MSM were exten-
sively assessed in previous studies; the GMT ratios between HM
and MSM were found to be similar with 9vHPV vaccine and qHPV
vaccine [11,20]. Thus it was not deemed necessary to conduct an
assessment of immunogenicity in MSM in this study.5. Conclusion
In conclusion, a three-dose regimen of the 9vHPV vaccine eli-
cited a similar antibody response to HPV 6/11/16/18 as did the
qHPV vaccine in men aged 16–26 years. The safety and tolerability
profile was also generally similar for the two vaccines. Based on
these results, the efficacy of the 9vHPV vaccine is inferred to be
comparable with that of the qHPV vaccine. Furthermore, the
9vHPV vaccine could offer additional benefits by targeting HPV
types 31/33/45/52/58, which are responsible for 8% of HPV-
related anal cancers and 15% of HPV-related penile cancers [4,21].Disclosures and contributions
Disclosures
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stock options in the company. PVD acts as coordinating and princi-
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on the scientific advisory board (expert meeting) of GSK, Qiagen,
Table 3
Summary of month 7 GMTs in the 9vHPV vaccine and qHPV vaccine groups; HPV-specific per-protocol immunogenicity set.
Assay 9vHPV vaccine N = 249 qHPV vaccine N = 251 Estimated GMT ratio 9vHPV/qHPV (95% CI)
n GMT (mMU/mL) 95% CI n GMT (mMU/mL)a 95% CIa
Anti-HPV 6
All 228 758.3 665.9; 863.4 226 618.4 554.0; 690.3 1.23 (1.04; 1.45)b
16–17 y 36 1284.5 1009.0; 1635.2 36 1012.7 794.0; 1291.6
18–26 y 192 686.9 594.8; 793.2 190 563.2 500.2; 634.2
Anti-HPV 11
All 228 681.7 608.9; 763.4 226 769.1 683.5; 865.3 0.89 (0.76; 1.04)b
16–17 y 36 1138.6 889.4; 1457.5 36 1119.3 859.7; 1457.2
18–26 y 192 619.2 548.1; 699.7 190 716.3 629.3; 815.3
Anti-HPV 16
All 234 3924.1 3513.8; 4382.3 237 3787.9 3378.4; 4247.0 1.04 (0.89; 1.21)b
16–17 y 36 5868.0 4486.1; 7675.6 37 6045.7 4445.0; 8222.9
18–26 y 198 3647.2 3237.5; 4108.7 200 3474.0 3079.9; 3918.6
Anti-HPV 18
All 234 884.3 766.4; 1020.4 236 790.9 683.0; 915.7 1.12 (0.91; 1.37)b
16–17 y 36 1390.4 989.6; 1953.6 36 1346.2 951.1; 1905.4
18–26 y 198 814.5 696.9; 951.8 200 718.7 613.1; 842.3
Anti-HPV 31
All 234 794.4 694.2; 909.2 237 14.8 12.5; 17.5
16–17 y 36 1441.9 999.1; 2080.9 36 22.0 13.8; 35.1
18–26 y 198 712.8 619.1; 820.8 201 13.8 11.5; 16.5
Anti-HPV 33
All 236 460.5 410.6; 516.4 236 3.4 3.1; 3.7
16–17 y 36 778.8 586.0; 1035.1 37 4.4 3.4; 5.7
18–26 y 200 418.9 371.0; 473.1 199 3.2 2.9; 3.5
Anti-HPV 45
All 232 262.9 226.2; 305.5 236 2.5 2.3; 2.8
16–17 y 34 479.1 321.9; 713.3 37 3.3 2.4; 4.6
18–26 y 198 237.1 202.3; 278.1 199 2.4 2.1; 2.6
Anti-HPV 52
All 235 430.7 377.8; 491.0 236 1.9 1.8; 2.1
16–17 y 36 773.6 551.7; 1084.7 37 2.5 2.0; 3.1
18–26 y 199 387.4 337.4; 444.8 199 1.9 1.7; 2.0
Anti-HPV 58
All 232 691.0 614.9; 776.5 233 5.7 5.0; 6.5
16–17 y 35 1259.1 938.1; 1690.1 36 9.0 6.0; 13.4
18–26 y 197 621.1 549.8; 701.8 197 5.2 4.6; 6.0
CI, confidence interval; GMT, geometric mean titres; mMU, milli-Merck units; N, number of randomised participants in the respective vaccination group; n, number of
participants contributing to the analysis; y, years.
a The estimated GMT ratio and associated CI are based on an analysis of variance (ANOVA) model including group and age strata as independent variables.
b Non-inferiority was achieved if the lower bound of the 2-sided 95% CI for the GMT ratio was greater than 0.50.
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Table 4
Summary of month 7 seropositivity rates in the 9vHPV vaccine and qHPV vaccine groups; HPV-specific per-protocol immunogenicity set.
Assay 9vHPV vaccine N = 249 qHPV vaccine N = 251
n m % 95% CI n m % 95% CI⁄
Anti-HPV 6 228 224 98.2 95.6; 99.5 226 223 98.7 96.2; 99.7
Anti-HPV 11 228 228 100 98.4; 100 226 226 100 98.4; 100
Anti-HPV 16 234 234 100 98.4; 100 237 237 100 98.5; 100
Anti-HPV 18 234 233 99.6 97.6; 100 236 235 99.6 97.7; 100
Anti-HPV 31 234 234 100 98.4; 100 237 146 61.6 55.1; 67.8
Anti-HPV 33 236 236 100 98.4; 100 236 40 16.9 12.4; 22.4
Anti-HPV 45 232 232 100 98.4; 100 236 22 9.3 5.9; 13.8
Anti-HPV 52 235 235 100 98.4; 100 236 6 2.5 0.9; 5.5
Anti-HPV 58 232 232 100 98.4; 100 233 84 36.1 29.9; 42.6
CI, confidence interval; N, number of randomised participants in the respective vaccination group; n, number of participants contributing to the analysis; m, number of
participants changing serostatus from seronegative to seropositive; seropositive represents the percent of participants with anti-HPV serum levelsP30, 16, 20, 24, 10, 8, 8, 8,
and 8 milli-Merck units/mL for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, respectively.
Table 5
Summary of safety for days 1–15 following either vaccination; safety set.
9vHPV vaccine N = 248 qHPV vaccine N = 248
n (%) n (%)
No adverse events 44 (17.7) 45 (18.1)
One or more adverse events 204 (82.3) 203 (81.9)
One or more vaccine-related adverse reactions 202 (81.5) 196 (79.0)
Injection-site adverse reaction 196 (79.0) 179 (72.2)
Solicited injection-site adverse reaction 195 (78.6) 177 (71.4)
Injection site erythema 38 (15.3) 43 (17.3)
Injection site swelling 36 (14.5) 23 (9.3)
Injection site pain 193 (77.8) 174 (70.2)
Other injection-site adverse reaction 24 (9.7) 23 (9.3)
Severe injection-site adverse reaction 3 (1.2) 4 (1.6)
Systemic adverse events 101 (40.7) 100 (40.3)
Vaccine-related systemic adverse event 57 (23.0) 54 (21.8)
Serious adverse events 0 (0) 0 (0)
Vaccine-related serious adverse event at any time 0 (0) 0 (0)
Serious adverse events leading to death 0 (0) 0 (0)
Withdrawn due to an adverse event 0 (0) 0 (0)
CI, confidence interval; N, number of participants in the respective vaccination group; n, number of participants reporting at least one event.
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